51. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL
- Author
-
Li, Benshang, Li, Hui, Bai, Yun, Kirschner-Schwabe, Renate, Yang, Jun J., Chen, Yao, Lu, Gang, Tzoneva, Gannie, Ma, Xiaotu, Wu, Tongmin, Li, Wenjing, Lu, Haisong, Ding, Lixia, Liang, Huanhuan, Huang, Xiaohang, Yang, Minjun, Jin, Lei, Kang, Hui, Chen, Shuting, Du, Alicia, Shen, Shuhong, Ding, Jianping, Chen, Hongzhuan, Chen, Jing, von Stackelberg, Arend, Gu, Longjun, Zhang, Jinghui, Ferrando, Adolfo, Tang, Jingyan, Wang, Shengyue, and Zhou, Bin-Bing S.
- Subjects
Gene mutations -- Physiological aspects -- Research ,Acute lymphocytic leukemia -- Genetic aspects -- Drug therapy -- Research ,Chemotherapy -- Health aspects -- Physiological aspects -- Genetic aspects -- Research ,Cancer -- Chemotherapy ,Phosphates -- Health aspects -- Physiological aspects -- Genetic aspects -- Research ,Biological sciences ,Health - Abstract
Relapse is the leading cause of mortality in children with acute lymphoblastic leukemia (ALL). Among chemotherapeutics, thiopurines are key drugs in ALL combination therapy. Using whole-exome sequencing, we identified relapse-specific mutations in the phosphoribosyl pyrophosphate synthetase 1 gene (PRPS1), which encodes a rate-limiting purine biosynthesis enzyme, in 24/358 (6.7%) relapsed childhood B cell ALL (B-ALL) cases. All individuals who harbored PRPS1 mutations relapsed early during treatment, and mutated ALL clones expanded exponentially before clinical relapse. Our functional analyses of PRPS1 mutants uncovered a new chemotherapy-resistance mechanism involving reduced feedback inhibition of de novo purine biosynthesis and competitive inhibition of thiopurine activation. Notably, the de novo purine synthesis inhibitor lometrexol effectively abrogated PRPS1 mutant-driven drug resistance. These results highlight the importance of constitutive activation of the de novo purine synthesis pathway in thiopurine resistance, and they offer therapeutic strategies for the treatment of relapsed and thiopurine-resistant ALL., Relapsed ALL remains a leading cause of mortality among all childhood malignancies in spite of risk-stratified combination therapy and improved supportive care (1). The thiopurines 6-mercaptopurine (6-MP) and 6-thioguanine (6-TG) [...]
- Published
- 2015
- Full Text
- View/download PDF